Información de Novartis AG, dividendo de Novartis AG, actividades de los accionistas y más

Información de Novartis AG Compañía

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Información de la empresa

Código de la empresaNVS

Nombre de la empresaNovartis AG

Fecha de salida a bolsaMay 07, 2001

Fundada en1996

Director ejecutivoDr. Vasant (Vas) Narasimhan, M.D.

Número de empleados75883

Tipo de títulosOrdinary Share

Fin del año fiscalMay 07

DirecciónLichtstrasse 35

CiudadBASEL

Bolsa de valoresJohannesburg Stock Exchange

PaísSwitzerland

Código postal4056

Teléfono41613241111

Sitio Webhttps://www.novartis.com/

Código de la empresaNVS

Fecha de salida a bolsaMay 07, 2001

Fundada en1996

Ejecutivos de la empresa

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Mr. Patrick Horber, M.D.

President - International, Member of the Executive Committee

--

Ms. Ana de Pro Gonzalo

Non-Executive Independent Director

--

Ms. Elizabeth Mcnally

Director

--

Mr. Giovanni Caforio

Chairman of the Board

--

Mr. John D. Young

Non-Executive Independent Director

--

Dr. Robert (Rob) Kowalski

Chief People and Organization Officer, Member of the Executive Committee

--

Dr. Fiona H. Marshall, Ph.D.

President - Biomedical Research, Member of the Executive Committee

--

Dr. Shreeram Aradhye, M.D.

President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee

--

Dr. Simon E. Moroney

Independent Non-Executive Vice Chairman of the Board

--

Ms. Karen L. Hale

Chief Legal Officer, Member of the Executive Committee

--

Nombre

Nombre/Posición

Posición

Accionados

Cambio

Mr. Patrick Horber, M.D.

President - International, Member of the Executive Committee

--

Ms. Ana de Pro Gonzalo

Non-Executive Independent Director

--

Ms. Elizabeth Mcnally

Director

--

Mr. Giovanni Caforio

Chairman of the Board

--

Mr. John D. Young

Non-Executive Independent Director

--

Dr. Robert (Rob) Kowalski

Chief People and Organization Officer, Member of the Executive Committee

--

Desglose de ingresos

Divisa: USDHora de actualización: dom., 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Rest of portfolio

10.07B

20.02%

Cardiovascular, Renal and Metabolism - Entresto

7.82B

15.55%

Immunology - Cosentyx

6.14B

12.20%

Neuroscience - Kesimpta

3.22B

6.41%

Oncology -Kisqali

3.03B

6.03%

Other

20.02B

39.80%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

21.15B

42.03%

Other Foreign-

18.51B

36.79%

China

3.89B

7.73%

Germany

3.66B

7.27%

France

1.79B

3.56%

Switzerland

1.31B

2.61%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Rest of portfolio

10.07B

20.02%

Cardiovascular, Renal and Metabolism - Entresto

7.82B

15.55%

Immunology - Cosentyx

6.14B

12.20%

Neuroscience - Kesimpta

3.22B

6.41%

Oncology -Kisqali

3.03B

6.03%

Other

20.02B

39.80%

Accionista

Hora de actualización: vie., 28 de mar

Estadísticas de accionistas

Tipo

Estadísticas de accionistas

Accionista

Proporción

Dodge & Cox

0.62%

PRIMECAP Management Company

0.56%

Dimensional Fund Advisors, L.P.

0.41%

Loomis, Sayles & Company, L.P.

0.28%

Franklin Mutual Advisers, LLC

0.22%

Other

97.91%

Estadísticas de accionistas

Accionista

Proporción

Dodge & Cox

0.62%

PRIMECAP Management Company

0.56%

Dimensional Fund Advisors, L.P.

0.41%

Loomis, Sayles & Company, L.P.

0.28%

Franklin Mutual Advisers, LLC

0.22%

Other

97.91%

Tipo

Accionista

Proporción

Investment Advisor

3.26%

Investment Advisor/Hedge Fund

2.64%

Research Firm

0.37%

Hedge Fund

0.28%

Bank and Trust

0.12%

Pension Fund

0.03%

Family Office

0.01%

Other

93.29%

Participación institucional

Hora de actualización: jue., 20 de feb

Periodo de informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q1

1884

133.48M

6.75%

-9.09M

2024Q4

1926

134.00M

6.78%

-9.24M

2024Q3

1858

134.89M

6.74%

-11.71M

2024Q2

1840

139.20M

6.87%

-9.16M

2024Q1

1808

141.30M

6.92%

-7.93M

2023Q4

1811

141.99M

6.94%

-15.97M

2023Q3

1775

150.92M

7.33%

-7.18M

2023Q2

1759

150.74M

7.28%

-24.15M

2023Q1

1762

167.49M

7.98%

-13.01M

2022Q4

1782

173.67M

8.19%

-17.15M

Actividad de los accionistas

Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Dodge & Cox

12.21M

0.62%

-7.21K

-0.06%

Dec 31, 2024

PRIMECAP Management Company

11.03M

0.56%

-983.02K

-8.19%

Dec 31, 2024

Dimensional Fund Advisors, L.P.

8.18M

0.41%

+90.82K

+1.12%

Dec 31, 2024

Loomis, Sayles & Company, L.P.

5.58M

0.28%

-192.68K

-3.34%

Dec 31, 2024

Franklin Mutual Advisers, LLC

4.26M

0.22%

-16.98K

-0.40%

Dec 31, 2024

Wellington Management Company, LLP

3.65M

0.18%

-351.31K

-8.78%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

3.59M

0.18%

-52.88K

-1.45%

Dec 31, 2024

Parametric Portfolio Associates LLC

2.98M

0.15%

-86.17K

-2.81%

Dec 31, 2024

Managed Account Advisors LLC

2.95M

0.15%

-214.17K

-6.76%

Dec 31, 2024

Renaissance Technologies LLC

2.67M

0.14%

+368.17K

+16.00%

Dec 31, 2024

ETF relacionados

Hora de actualización: dom., 6 de abr

Nombre

Proporción

VanEck Pharmaceutical ETF

5.37%

Cullen Enhanced Equity Income ETF

4.16%

Invesco International Dividend Achievers ETF

2.69%

Amplify International Enhanced Dividend Income ETF

2.67%

Altrius Global Dividend ETF

2.35%

SGI Enhanced Global Income ETF

2.07%

Pacer Global Cash Cows Dividend ETF

2.06%

Abacus FCF International Leaders ETF

1.9%

SP Funds S&P World (ex-US) ETF

1.78%

The Opal International Dividend Income ETF

1.74%

VanEck Pharmaceutical ETF

Proporción5.37%

Cullen Enhanced Equity Income ETF

Proporción4.16%

Invesco International Dividend Achievers ETF

Proporción2.69%

Amplify International Enhanced Dividend Income ETF

Proporción2.67%

Altrius Global Dividend ETF

Proporción2.35%

SGI Enhanced Global Income ETF

Proporción2.07%

Pacer Global Cash Cows Dividend ETF

Proporción2.06%

Abacus FCF International Leaders ETF

Proporción1.9%

SP Funds S&P World (ex-US) ETF

Proporción1.78%

The Opal International Dividend Income ETF

Proporción1.74%

Dividendos

Un total de 36.74B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Feb 20, 2025

NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025

Mar 12, 2025

May 01, 2025

Mar 12, 2025

Feb 12, 2024

NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024

Mar 08, 2024

Apr 19, 2024

Mar 07, 2024

Feb 02, 2023

NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023

Mar 10, 2023

Mar 20, 2023

Mar 09, 2023

Feb 04, 2022

NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022

Mar 09, 2022

Mar 17, 2022

Mar 08, 2022

Jan 26, 2021

NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021

Mar 05, 2021

Mar 15, 2021

Mar 04, 2021

Jan 31, 2020

NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020

Mar 04, 2020

Mar 12, 2020

Mar 03, 2020

División de acciones

Fecha

Tipo

Relación

No datos encontrados

Fecha

Tipo

Relación

No datos encontrados

Novartis AG

101.970USD

Novartis AG

101.970

Descripción general

Compañía